WMA Declaration of Helsinki – Ethical Principles f... ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Ask the Heart Doctor | Heart Valve Disease and Sur...
Drug candidate slows motor neuron disease progress...
A Professional Overview of Hypertension ...
Long-term physical activity protects against metabolic syndr...
January 17,2026
Controlling hypertension can reduce dementia risk—even when ...
January 16,2026
Assessing methods for improving access to trauma care for ki...
January 15,2026
Portable device could help scientists track Alzheimer's dise...
January 14,2026
Neurons use physical signals, not electricity, to stabilize ...
January 13,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?

Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?

Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?Uses, Procedure, and ResultsByLynne Eldridge, MDUpdated on June 13, 2023Medically reviewed byDoru Paul,
Oncology March 17,2024
Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?

Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?

Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?Uses, Procedure, and ResultsByLynne Eldridge, MDUpdated on June 13, 2023Medically reviewed byDoru Paul,
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Dr. Fauci among hundreds who've contract...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
Announcement of the 2025 Nobel Prize in ...
More News
Researchers reveal why vaccines have lower efficacy in patients with multiple myeloma

Researchers reveal why vaccines have lower efficacy in patients with multiple myeloma

by Centro de Investigación Médica Aplicada (CIMA) Universidad de NavarraMicrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0Researc
Oncology August 28,2024
Researchers reveal why vaccines have lower efficacy in patients with multiple myeloma

Researchers reveal why vaccines have lower efficacy in patients with multiple myeloma

by Centro de Investigación Médica Aplicada (CIMA) Universidad de NavarraMicrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0Researc
Oncology August 28,2024
Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics

Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics

byBrigham and Women’s HospitalGlobal characterization of the melanoma samples and their expression of CEACAM1. Credit:Communications Medicine(2024). DOI: 10.1038/s43856-024-00525-8Yu
Oncology August 28,2024
Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics

Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics

byBrigham and Women’s HospitalGlobal characterization of the melanoma samples and their expression of CEACAM1. Credit:Communications Medicine(2024). DOI: 10.1038/s43856-024-00525-8Yu
Oncology August 28,2024
Novel approach to study hypoxia enables identification of a marker for ovarian cancers

Novel approach to study hypoxia enables identification of a marker for ovarian cancers

by Myreille Larouche,University of MontrealLong-term severe hypoxia adaptation induces EMT-like morphological changes. Credit:Cancer Gene Therapy(2024). DOI: 10.1038/s41417-024-00795
Oncology August 28,2024
Novel approach to study hypoxia enables identification of a marker for ovarian cancers

Novel approach to study hypoxia enables identification of a marker for ovarian cancers

by Myreille Larouche,University of MontrealLong-term severe hypoxia adaptation induces EMT-like morphological changes. Credit:Cancer Gene Therapy(2024). DOI: 10.1038/s41417-024-00795
Oncology August 28,2024
Immune landscape and response to oncolytic virus-based immunotherapy

Immune landscape and response to oncolytic virus-based immunotherapy

by Frontiers JournalsCredit:Frontiers of Medicine(2024). DOI: 10.1007/s11684-023-1048-0Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, of
Oncology August 28,2024
Immune landscape and response to oncolytic virus-based immunotherapy

Immune landscape and response to oncolytic virus-based immunotherapy

by Frontiers JournalsCredit:Frontiers of Medicine(2024). DOI: 10.1007/s11684-023-1048-0Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, of
Oncology August 28,2024
Age impacts pharmacogenomics and treatment outcomes for most common form of leukemia

Age impacts pharmacogenomics and treatment outcomes for most common form of leukemia

bySt. Jude Children's Research HospitalJun J. Yang, PhD, St. Jude Departments of Pharmacy and Pharmaceutical Sciences and Oncology and first co-authors Zhenhua Li, PhD, and Satoshi Yoshimura
Oncology August 28,2024
Age impacts pharmacogenomics and treatment outcomes for most common form of leukemia

Age impacts pharmacogenomics and treatment outcomes for most common form of leukemia

bySt. Jude Children's Research HospitalJun J. Yang, PhD, St. Jude Departments of Pharmacy and Pharmaceutical Sciences and Oncology and first co-authors Zhenhua Li, PhD, and Satoshi Yoshimura
Oncology August 28,2024
Scientists create cost-effective, easy-to-use test to categorize a child's cancer and guide better treatment

Scientists create cost-effective, easy-to-use test to categorize a child's cancer and guide better treatment

bySt. Jude Children's Research Hospital(L to R) Co-corresponding author Jeff Klco, MD, PhD, St. Jude Department of Pathology, co-corresponding author Xiaotu Ma, PhD, St. Jude Department of C
Oncology August 28,2024
Scientists create cost-effective, easy-to-use test to categorize a child's cancer and guide better treatment

Scientists create cost-effective, easy-to-use test to categorize a child's cancer and guide better treatment

bySt. Jude Children's Research Hospital(L to R) Co-corresponding author Jeff Klco, MD, PhD, St. Jude Department of Pathology, co-corresponding author Xiaotu Ma, PhD, St. Jude Department of C
Oncology August 28,2024
Using AI, researchers pioneer a potential new immunotherapy approach for treating glioblastoma

Using AI, researchers pioneer a potential new immunotherapy approach for treating glioblastoma

byKeck School of Medicine of USCGlioblastoma (histology slide). Credit: Wikipedia/CC BY-SA 3.0In an innovative study of glioblastoma, scientists used artificial intelligence (AI) to reprogram ca
Oncology August 28,2024
Using AI, researchers pioneer a potential new immunotherapy approach for treating glioblastoma

Using AI, researchers pioneer a potential new immunotherapy approach for treating glioblastoma

byKeck School of Medicine of USCGlioblastoma (histology slide). Credit: Wikipedia/CC BY-SA 3.0In an innovative study of glioblastoma, scientists used artificial intelligence (AI) to reprogram ca
Oncology August 28,2024
New hope for prostate cancer: New form of immunotherapy could prevent resistance to hormone therapy

New hope for prostate cancer: New form of immunotherapy could prevent resistance to hormone therapy

byUniversity of SheffieldADT stimulates the PV accumulation of FR-β+ TAMs in mouse (Myc-CaP) and localized, human prostate tumors. Credit:Journal for ImmunoTherapy of Cancer(2024). D
Oncology August 28,2024
New hope for prostate cancer: New form of immunotherapy could prevent resistance to hormone therapy

New hope for prostate cancer: New form of immunotherapy could prevent resistance to hormone therapy

byUniversity of SheffieldADT stimulates the PV accumulation of FR-β+ TAMs in mouse (Myc-CaP) and localized, human prostate tumors. Credit:Journal for ImmunoTherapy of Cancer(2024). D
Oncology August 28,2024
AI tool 'DeepHRD' accelerates cancer treatment decisions

AI tool 'DeepHRD' accelerates cancer treatment decisions

byUniversity of California - San DiegoFirst author Erik Bergstrom showcasing a biopsy analysis completed with DeepHRD, a new artificial intelligence tool that can detect clinically actionable ge
Oncology August 28,2024
AI tool 'DeepHRD' accelerates cancer treatment decisions

AI tool 'DeepHRD' accelerates cancer treatment decisions

byUniversity of California - San DiegoFirst author Erik Bergstrom showcasing a biopsy analysis completed with DeepHRD, a new artificial intelligence tool that can detect clinically actionable ge
Oncology August 28,2024
Drug bypasses suppressive immune cells to unleash immunotherapy

Drug bypasses suppressive immune cells to unleash immunotherapy

by Marta Wegorzewska,Washington University School of MedicineImmunobiologists Robert Schreiber, Ph.D., (left) and Hussein Sultan, Ph.D., of Washington University School of Medicine in St. Louis,
Oncology August 28,2024
Drug bypasses suppressive immune cells to unleash immunotherapy

Drug bypasses suppressive immune cells to unleash immunotherapy

by Marta Wegorzewska,Washington University School of MedicineImmunobiologists Robert Schreiber, Ph.D., (left) and Hussein Sultan, Ph.D., of Washington University School of Medicine in St. Louis,
Oncology August 28,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... Health spending has been rising across rich countries with different systems ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com